INTERFERON ALFA-2B THERAPY IN MUCOCUTANEOUS MANIFESTATIONS OF BEHCET'S DISEASE

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

REZAEI YAZDI Z.; SHOJA-E-RAZAVI G.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: IRANIAN JOURNAL OF MEDICAL SCIENCES (IJMS) Year:2005 | Volume:30 | Issue:3 Page(s): 105-109

Download Full-Text

View:

377

Download:

105

Cites:

Information Journal Paper

Title

INTERFERON ALFA-2B THERAPY IN MUCOCUTANEOUS MANIFESTATIONS OF BEHCET'S DISEASE

Author(s)

REZAEI YAZDI Z. | SHOJA-E-RAZAVI G. | Issue Writer Certificate

Keywords

BEHCET. DISEASE . MUCOCUTANEOUS LESIONS . INF-A#2B

Abstract

Background: Viral infections such as Epstein-Barr virus and Herpes simplex virus may play a role in the pathogenesis of Behçet’s disease (BD). Interferons (INF) are natural defense mechanisms against viruses and inhibit their activities by enhancing major histocompatibility complex class I and cytokine expression. This study evaluated the efficacy of INF-α-2b on mucocutaneous lesions of BD. Methods: In this open label clinical trial, 12 patients were chosen sequentially from cases referred to the Rheumatology Unit of the Ghaem Hospital of Mashhad University of Medical Sciences, Mashhad, Iran, with inclusion criteria of active BD without central nervous system or ophthalmic involvement. They received subcutaneous injections of 3 million units of IFN-α-2b three times a week for six months. The numbers and the sizes of lesions were evaluated monthly with the objective and subjective assessments of disease activity. Results: The average dose of interferon prescribed was 2.71 million units during six months. The numbers and sizes of oral, genital and cutaneous lesions decreased significantly with less pain and longer duration of remission. The most common side effects were flu-like symptoms and bone pain reported by 8 patients with temporary impotence in two males and local reactions as erythema and edema of the upper extremities in two patients. Conclusion: INF-α-2b seems to be an effective therapy for mucocutaneous lesions of Behçet’s disease.

Cites

No record.

References

No record.

Cite

APA: Copy

REZAEI YAZDI, Z., & SHOJA-E-RAZAVI, G.. (2005). INTERFERON ALFA-2B THERAPY IN MUCOCUTANEOUS MANIFESTATIONS OF BEHCET'S DISEASE. IRANIAN JOURNAL OF MEDICAL SCIENCES (IJMS), 30(3), 105-109. SID. https://sid.ir/paper/275973/en

Vancouver: Copy

REZAEI YAZDI Z., SHOJA-E-RAZAVI G.. INTERFERON ALFA-2B THERAPY IN MUCOCUTANEOUS MANIFESTATIONS OF BEHCET'S DISEASE. IRANIAN JOURNAL OF MEDICAL SCIENCES (IJMS)[Internet]. 2005;30(3):105-109. Available from: https://sid.ir/paper/275973/en

IEEE: Copy

Z. REZAEI YAZDI, and G. SHOJA-E-RAZAVI, “INTERFERON ALFA-2B THERAPY IN MUCOCUTANEOUS MANIFESTATIONS OF BEHCET'S DISEASE,” IRANIAN JOURNAL OF MEDICAL SCIENCES (IJMS), vol. 30, no. 3, pp. 105–109, 2005, [Online]. Available: https://sid.ir/paper/275973/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops